Curetis

New funding will support assay development and lab space to offer test services, and ultimately a test kit using the firm's resistance database.

The company will rely more on distribution partners in Europe for its Unyvero product line while continuing highly targeted commercialization efforts in the US.

The three-year extension increases the minimum purchase commitments for the Unyvero system, resulting in an increase in potential revenues of €30 million to Curetis.

The firm will use the funds to continue its commercialization plans for the Unyvero diagnostic test cartridges and instruments.

The revenue increase was driven by surging direct sales of the firm's diagnostic test cartridges in Europe, the Middle East, and Asia.

As part of the agreements, the distributors have committed to purchase a minimum number of Curetis' molecular diagnostic systems over three years.

The revenue increase was driven in part by surging direct sales of the firm's diagnostic test cartridges and instruments in Europe, the Middle East, and Asia.

Revenues fell as an increase in sales of test cartridges for its Unyvero molecular diagnostic instrument was offset by a decline in system and service sales.

The company said it will use the proceeds for the US commercial launch of its Unyvero molecular diagnostic platform, among other things.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.